UBS Group upgraded shares of GALAPAGOS NV/S (NASDAQ:GLPG) from a neutral rating to a buy rating in a report released on Wednesday morning, BenzingaRatingsTable reports.
GLPG has been the subject of a number of other research reports. Cantor Fitzgerald reaffirmed a buy rating and issued a $130.00 price objective on shares of GALAPAGOS NV/S in a research note on Thursday, May 2nd. Morgan Stanley raised their price objective on shares of GALAPAGOS NV/S from $138.00 to $139.00 and gave the stock an overweight rating in a research note on Monday, April 29th. Stifel Nicolaus raised their price objective on shares of GALAPAGOS NV/S from $121.00 to $188.00 and gave the stock a buy rating in a research note on Monday, July 15th. Nomura raised their price objective on shares of GALAPAGOS NV/S from $140.00 to $209.00 and gave the stock a buy rating in a research note on Monday, July 29th. Finally, Cowen reissued a buy rating on shares of GALAPAGOS NV/S in a research note on Friday, July 26th. Three research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $156.45.
GALAPAGOS NV/S stock traded down $1.74 during midday trading on Wednesday, reaching $172.49. The stock had a trading volume of 108,134 shares, compared to its average volume of 327,593. The firm has a fifty day moving average of $149.07. GALAPAGOS NV/S has a twelve month low of $85.00 and a twelve month high of $191.63. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.40 and a current ratio of 6.40. The firm has a market cap of $8.88 billion, a price-to-earnings ratio of -261.35 and a beta of 1.56.
About GALAPAGOS NV/S
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Featured Story: When can a hold rating present a buying opportunity?
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.